Spago Nanomedical Announces Positive Data and Dose Increase Recommendation for 177Lu-SN201 in Phase I/IIa Tumorad-01 Study

Spago Nanomedical announced that the Data Monitoring Committee (DMC) recommended a dose increase in the ongoing Phase I/IIa clinical trial Tumorad-01 ...

Empowering Life Sciences with
Advanced AI Solutions.

Book A Demo
HomeKnolsightsContact UsPricing
One Research Court, Suite 450, Rockville, MD 20850
info@pienomial.com
+91 9876543210
© 2025 Pienomial. All rights reserved
AboutTerms of ServicePrivacy Policy
Home/KnloSights/Clinical Trial Updates/Spago Nanomedical Announces Positive Data and Dose Increase Recommendation for 177Lu-SN201 in Phase I/IIa Tumorad-01 Study